Conduction Defects/Cardiomyopathies

Advances in Pediatrics

Volumn 61, Issue 1, 2014, Pages 127-148

  Gilbert Barness, Enid ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cardiac arrhythmias; Cardiomyopathies; Conduction disorders; Inherited diseases; Sudden death

Indexed keywords

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; CHILD; CONGENITAL MALFORMATION; DIAGNOSTIC IMAGING; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PROCEDURES;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; CHILD; DIAGNOSTIC IMAGING; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS;

EID: 84904278950     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2014.03.001     Document Type: Review

References (99)

1. Michaelsson M., Engle M. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972, 4:85-101.
2. Gruntheroth W.G., Motolsky A.G. Inherited disorders of cardiac rhythm and conduction. Prog Med Genet 1983, 5:581.
3. McCue C.M., Mantakas M.E., Tingelstad J.B., et al. Congenital heart block in newborns of mothers with connective tissue disease. Circulation 1977, 56(1):82-90.
4. Lev M. Pathogenesis of congenital atrioventricular block. Prog Cardiovasc Dis 1972, 15(2):145-157.
5. Shenker L. Fetal cardiac arrhythmias. Obstet Gynecol Surv 1979, 34(8):561-572.
6. Bulkley B.H., Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975, 58(2):243-264.
7. Scott J.S., Maddison P.J., Taylor P.V., et al. Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. NEngl J Med 1983, 309(4):209-212.
8. Litsey S.E., Noonan J.A., O'Connor W.N., et al. Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue. NEngl J Med 1985, 312(2):98-100.
9. Petri M., Watson R., Hochberg M.C. Anti-Ro antibodies and neonatal lupus. Rheum Dis Clin North Am 1989, 15(2):335-360.
10. Neyroud N., Tesson F., Denjoy I., et al. Anovel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 1997, 15(2):186-189.
11. Compton S.J., Lux R.L., Ramsey M.R., et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996, 94(5):1018-1022.
12. Hallman K., Carlsson L. Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol Toxicol 1995, 77(4):250-254.
13. Chinushi M., Aizawa Y., Furushima H., et al. Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome. Jpn Heart J 1995, 36(4):477-481.
14. Vincent G., Fox J., Zhang L. Effects of potassium channel opener in KVLQT1 long QT gene carriers. JAm Coll Cardiol 1997, 29:183A.
15. Sato T., Hata Y., Yamamoto M., et al. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. JCardiovasc Electrophysiol 1995, 6(4):279-282.
16. Shimizu W., Ohe T., Kurita T., et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. JAm Coll Cardiol 1995, 26(5):1299-1309.
17. Priori S.G., Napolitano C., Cantu F., et al. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. Circ Res 1996, 78(6):1009-1015.
18. Schwartz P.J., Priori S.G., Locati E.H., et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995, 92(12):3381-3386.
19. Barth P.G., Vant Veer-korthof E.T., Van Delden L., et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leukocytes 1981, 161-164. Mefar, Beetsterzwaag (The Netherlands). H.F.M. Busch, F.G.I. Jennekens, H.R. Schotte (Eds.).
20. Barth P.G., Scholte J.A., Berden J.A., et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leukocytes. J Neurol Sci 1983, 62:327-355.
21. Hodgson S., Child A., Dyson M. Endocardial fibroelastosis: possible X linked inheritance. JMed Genet 1987, 24(4):210-214.
22. Neustein H.B., Lurie P.R., Dahms B., et al. An X-linked recessive cardiomyopathy with abnormal mitochondria. Pediatrics 1979, 64(1):24-29.
23. Kelly R., Clark B., Morton D., et al. X-linked cardiomyopathy, neutropenia and increased urinary levels of 3-methylglutaconic and 2-ethylhydracrylic acids. Am J Hum Genet 1989, 45(Suppl).
24. Kelley R.I., Cheatham J.P., Clark B.J., et al. X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. JPediatr 1991, 119(5):738-747.
25. Orstavik K.H., Skjorten F., Hellebostad M., et al. Possible X linked congenital mitochondrial cardiomyopathy in three families. JMed Genet 1993, 30(4):269-272.
26. Barth P.G., Scholte H.R., Berden J.A., et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. JNeurol Sci 1983, 62(1-3):327-355.
27. Bolhuis P.A., Hensels G.W., Hulsebos T.J., et al. Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. Am J Hum Genet 1991, 48(3):481-485.
28. Bione S., D'Adamo P., Maestrini E., et al. Anovel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet 1996, 12(4):385-389.
29. Barth P.G., Valianpour F., Bowen V.M., et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet A 2004, 126A(4):349-354.
30. Neuwald A.F. Barth syndrome may be due to an acyltransferase deficiency. Curr Biol 1997, 7(8):R465-R466.
31. Vreken P., Valianpour F., Nijtmans L.G., et al. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun 2000, 279(2):378-382.
32. Schhlame M., Towbin J., Jehle R., et al. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol 2002, 51:634-637.
33. Chin T.K., Perloff J.K., Williams R.G., et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 1990, 82(2):507-513.
34. Ritter M., Oechslin E., Sutsch G., et al. Isolated noncompaction of the myocardium in adults. Mayo Clin Proc 1997, 72(1):26-31.
35. Jenni R., Oechslin E., Schneider J., et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart 2001, 86(6):666-671.
36. Pignatelli R.H., McMahon C.J., Dreyer W.J., et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation 2003, 108(21):2672-2678.
37. Michel R.S., Carpenter M.A., Lovell M.A. Pathological case of the month. Noncompaction of the left ventricular myocardium. Arch Pediatr Adolesc Med 1998, 152(7):709-710.
38. Gilbert-Barness E. Review: metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci 2004, 34(1):15-34.
39. Manyari D.E., Klein G.J., Gulamhusein S., et al. Arrhythmogenic right ventricular dysplasia: a generalized cardiomyopathy?. Circulation 1983, 68(2):251-257.
40. Hermida J.S., Minassian A., Jarry G., et al. Familial incidence of late ventricular potentials and electrocardiographic abnormalities in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1997, 79(10):1375-1380.
41. Rampazzo A., Nava A., Malacrida S., et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002, 71(5):1200-1206.
42. Protonotarios N., Tsatsopoulou A., Patsourakos P., et al. Cardiac abnormalities in familial palmoplantar keratosis. Br Heart J 1986, 56(4):321-326.
43. Rampazzo A., Nava A., Danieli P., et al. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Molec Genet 1994, 3:959-962.
44. Rampazzo A., Nava A., Erne P., et al. Anew locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Hum Mol Genet 1995, 4(11):2151-2154.
45. Severini G.M., Krajinovic M., Pinamonti B., et al. Anew locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. Genomics 1996, 31(2):193-200.
46. Rampazzo A., Nava A., Miorin M., et al. ARVD4, a new focus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. Genomics 1997, 45(2):259-263.
47. Ahmad F., Li D., Karibe A., et al. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 1998, 98(25):2791-2795.
48. Hodgkinson K.A., Parfrey P.S., Bassett A.S., et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). JAm Coll Cardiol 2005, 45(3):400-408.
49. Li D., Ahmad F., Gardner M.J., et al. The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14. Am J Hum Genet 2000, 66(1):148-156.
50. Melberg A., Oldfors A., Blomstrom-Lundqvist C., et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann Neurol 1999, 46(5):684-692.
51. Gerull B., Heuser A., Wichter T., et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004, 36(11):1162-1164.
52. Sen-Chowdhry S., Syrris P., McKenna W.J. Genetics of right ventricular cardiomyopathy. JCardiovasc Electrophysiol 2005, 16(8):927-935.
53. Kullo L., Edwards W., Seward J. Right ventricular dysplasia: the Mayo Clinic experience. Mayo Clin Proc 1995, 70:541-548.
54. Wichter T., Breithardt G. Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy. A role for genotyping in decision-making?. JAm Coll Cardiol 2005, 45:409.
55. Prahlow J.A., Teot L.A. Histiocytoid cardiomyopathy: case report and literature review. JForensic Sci 1993, 38(6):1427-1435.
56. Witzleben C.L., Pinto M. Foamy myocardial transformation of infancy: 'lipid' or 'histiocytoid' myocardiopathy. Arch Pathol Lab Med 1978, 102(6):306-311.
57. Suarez V., Fuggle W.J., Cameron A.H., et al. Foamy myocardial transformation of infancy: an inherited disease. JClin Pathol 1987, 40(3):329-334.
58. Franciosi R.A., Singh A. Oncocytic cardiomyopathy syndrome. Hum Pathol 1988, 19(11):1361-1362.
59. Malhotra V., Ferrans V.J., Virmani R. Infantile histiocytoid cardiomyopathy: three cases and literature review. Am Heart J 1994, 128(5):1009-1021.
60. Zangwill S.D., Trost B.A., Zlotocha J., et al. Orthotopic heart transplantation in a child with histiocytoid cardiomyopathy. JHeart Lung Transplant 2004, 23(7):902-904.
61. Shehata B.M., Patterson K., Thomas J.E., et al. Histiocytoid cardiomyopathy: three new cases and a review of the literature. Pediatr Dev Pathol 1998, 1(1):56-69.
62. Bird L.M., Krous H.F., Eichenfield L.F., et al. Female infant with oncocytic cardiomyopathy and microphthalmia with linear skin defects (MLS): a clue to the pathogenesis of oncocytic cardiomyopathy?. Am J Med Genet 1994, 53(2):141-148.
63. Baillie T., Chan Y.F., Koelmeyer T.D., et al. Test and teach. Ill-defined subendocardial nodules in an infant. Histiocytoid cardiomyopathy. Pathology 2001, 33(2):230-234.
64. Vallance H.D., Jeven G., Wallace D.C., et al. Acase of sporadic infantile histiocytoid cardiomyopathy caused by the A8344G (MERRF) mitochondrial DNA mutation. Pediatr Cardiol 2004, 25(5):538-540.
65. Heifetz S.A., Faught P.R., Bauman M. Pathological case of the month. Histiocytoid (oncocytic) cardiomyopathy. Arch Pediatr Adolesc Med 1995, 149(4):464-465.
66. Ferrans V.J., McAllister H.A., Haese W.H. Infantile cardiomyopathy with histiocytoid change in cardiac muscle cells. Report of six patients. Circulation 1976, 53(4):708-719.
67. Saffitz J.E., Ferrans V.J., Rodriguez E.R., et al. Histiocytoid cardiomyopathy: a cause of sudden death in apparently healthy infants. Am J Cardiol 1983, 52(1):215-217.
68. Zimmerman A., Diem P., Cottier H. Congenital "histiocytoid" cardiomyopathy: evidence suggesting a developmental disorder of the Purkinje cell system of the heart. Virchows Arch A Pathol Anat Histol 1982, 396:187-195.
69. Ferrans V.J. Pathologic anatomy of the dilated cardiomyopathies. Am J Cardiol 1989, 64(6):9C-11C.
70. Kauffman S.L., Chandra N., Peress N.S., et al. Idiopathic infantile cardiomyopathy with involvement of the conduction system. Am J Cardiol 1972, 30(6):648-652.
71. Van Hare G.F. Radiofrequency catheter ablation of cardiac arrhythmias in pediatric patients. Adv Pediatr 1994, 41:83-109.
72. Gussak I., Brugada P., Brugada J., et al. Idiopathic short QT interval: a new clinical syndrome?. Cardiology 2000, 94(2):99-102.
73. Giustetto C., Di Monte F., Wolpert C., et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006, 27(20):2440-2447.
74. Bjerregaard P., Gussak I. Short QT syndrome: mechanisms, diagnosis and treatment. Nat Clin Pract Cardiovasc Med 2005, 2(2):84-87.
75. Brugada R., Hong K., Dumaine R., et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004, 109(1):30-35.
76. Bellocq C., van Ginneken A.C., Bezzina C.R., et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004, 109(20):2394-2397.
77. Hong K., Bjerregaard P., Gussak I., et al. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. JCardiovasc Electrophysiol 2005, 16(4):394-396.
78. Tseng G.N. I(Kr): the hERG channel. JMol Cell Cardiol 2001, 33(5):835-849.
79. Gaita F., Giustetto C., Bianchi F., et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003, 108(8):965-970.
80. Wren C., Rowland E., Burn J., et al. Familial ventricular tachycardia: a report of four families. Br Heart J 1990, 63(3):169-174.
81. Leenhardt A., Lucet V., Denjoy I., et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995, 91(5):1512-1519.
82. Fisher J.D., Krikler D., Hallidie-Smith K.A. Familial polymorphic ventricular arrhythmias: a quarter century of successful medical treatment based on serial exercise-pharmacologic testing. JAm Coll Cardiol 1993, 94:2015-2022.
83. Priori S.G., Napolitano C., Memmi M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106(1):69-74.
84. Swan H., Piippo K., Viitasalo M., et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. JAm Coll Cardiol 1999, 34(7):2035-2042.
85. Priori S.G., Napolitano C., Tiso N., et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001, 103(2):196-200.
86. Laitinen P.J., Brown K.M., Piippo K., et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001, 103(4):485-490.
87. Lahat H., Pras E., Olender T., et al. Amissense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001, 69(6):1378-1384.
88. Nof E., Lahat H., Constantini N., et al. Anovel form of familial bidirectional ventricular tachycardia. Am J Cardiol 2004, 93(2):231-234.
89. Wehrens X.H., Lehnart S.E., Huang F., et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003, 113(7):829-840.
90. Lahat H., Eldar M., Levy-Nissenbaum E., et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001, 103(23):2822-2827.
91. di Barletta M.R., Viatchenko-Karpinski S., Nori A., et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006, 114(10):1012-1019.
92. Eisenberg S.J., Scheinman M.M., Dullet N.K., et al. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. Am J Cardiol 1995, 75(10):687-692.
93. Wilde A.A., Bhuiyan Z.A., Crotti L., et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. NEngl J Med 2008, 358(19):2024-2029.
94. Tan J.H., Scheinman M.M. Exercise-induced polymorphic ventricular tachycardia in adults without structural heart disease. Am J Cardiol 2008, 101(8):1142-1146.
95. Tripp M.E., Katcher M.L., Peters H.A., et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. NEngl J Med 1981, 305(7):385-390.
96. Waber L.J., Valle D., Neill C., et al. Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. JPediatr 1982, 101(5):700-705.
97. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983, 63(4):1420-1480.
98. Karpati G., Carpenter S., Engel A.G., et al. The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology 1975, 25(1):16-24.
99. Pathogenetic mechanisms in human carnitine deficiency syndromes 1982, John-Wiley, New York. A. Engel, C. Rebouche (Eds.).